Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, our influenza vaccine candidate, has unique characteristics that stimulate multiple arms of the immune system and offers the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine. By leveraging the complementary attributes of its proprietary technology platforms, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including both acute and chronic infections and cancer. Source
No articles found.
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
CrowdMedâs patented prediction market technology can uncover diagnoses to real-w...
CrowdMedâs patented prediction market technol...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
Join the National Investor Network and get the latest information with your interests in mind.